{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:45:18Z","timestamp":1791265518652,"version":"4.1.0"},"reference-count":38,"publisher":"Endocrinology Research Centre","issue":"2","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> There is a lack of studies providing comprehensive data on the prevalence of mineral and bone disorders (MBD) laboratory abnormalities after kidney transplantation in Russia.<\/jats:p><jats:p><jats:bold>AIM:<\/jats:bold> to obtain real-world data on the prevalence of the main mineral abnormalities among kidney transplant recipients and to revise their concomitant MBD therapy.<\/jats:p><jats:p><jats:bold>METHOD:<\/jats:bold> This cross-sectional study included 236 patients with successful kidney transplantation. Their serum intact parathyroid hormone (iPTH), total calcium (Ca), phosphorus (P), and alkaline phosphatase (ALP) levels were measured.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Only 6.2% of our cohort had all laboratory parameters within the target range, whereas persistent HPT along with hypercalcemia was noted in almost one third of the patients (31%). Normal iPTH levels were observed in 13% cases; 84% of the patients had hyperparathyroidism. The fraction of patients with target iPTH did not differ between the groups with normal and decreased estimated glomerular filtration rate (eGFR) (p=0.118). Hypercalcemia was observed in 29% cases. The serum P level varied significantly in groups with different eGFR (p&lt;0.0001), increasing with declining graft function. Furthermore, 40.7% of patients had ALP above the target range. While 123 patients received active vitamin D (alfacalcidol), 33 received monotherapy with inactive vitamin D (cholecalciferol). The control group consisted of 57 medication-na\u00efve patients. The serum total Ca level varied significantly between the groups (p=0.0006), being higher in patients supplemented with cholecalciferol. The fraction of patients with normocalcemia was lowest in the cholecalciferol group (chi-square, \u0440=0.0018).<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> The prevalence of biochemical abnormalities after kidney transplantation is high. Alfacalcidol usage may be safer than using cholecalciferol to prevent hypercalcemia development.<\/jats:p>","DOI":"10.14341\/probl13167","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:47:44Z","timestamp":1684172864000},"page":"47-57","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":1,"title":["Pattern of biochemical markers of mineral and bone disorders in kidney transplant recipients: real-world data"],"prefix":"10.14341","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8497-0693","authenticated-orcid":true,"given":"A. V.","family":"Vatazin","sequence":"first","affiliation":[{"name":"Moscow Regional Research and Clinical Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-1824","authenticated-orcid":true,"given":"E. V.","family":"Parshina","sequence":"additional","affiliation":[{"name":"Saint-Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-7759","authenticated-orcid":true,"given":"R. O.","family":"Kantaria","sequence":"additional","affiliation":[{"name":"Moscow Regional Research and Clinical Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-0599","authenticated-orcid":true,"given":"V. A.","family":"Stepanov","sequence":"additional","affiliation":[{"name":"Moscow Regional Research and Clinical Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5405-7887","authenticated-orcid":true,"given":"A. B.","family":"Zulkarnaev","sequence":"additional","affiliation":[{"name":"Moscow Regional Research and Clinical Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5458","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Andrusev AM, Tomilina NA, Peregudova NG, Shinkarev MB. Renal replacement therapy of terminal chronic renal failure in the Russian Federation 2014\u20132018. Report on the data of the All-Russian Register of renal replacement therapy of the Russian Dialysis Society. Nephrology and dialysis. 2020;22(1):1-71. (In Russ.). doi: https:\/\/doi.org\/10.28996\/2618-9801-2020-1suppl-1-71","DOI":"10.28996\/2618-9801-2020-1suppl-1-71"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wolfe RA, Ashby VB, Milford EL, et al. Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant. N Engl J Med. 1999;341(23):1725-1730. doi: https:\/\/doi.org\/10.1056\/NEJM199912023412303","DOI":"10.1056\/NEJM199912023412303"},{"key":"ref3","unstructured":"Huffer WE, Kuzela D, Popovtzer MM, Starzl TE. Metabolic bone disease in chronic renal failure. II. Renal transplant patients. Am J Pathol. 1975;78(3):385-400."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Nielsen HE, Christensen MS, Melsen F, Torring S. Bone disease, hypophosphatemia and hyperparathyroidism after renal transplantation. Adv Exp Med Biol. 1977;(81):603-610. doi: https:\/\/doi.org\/10.1007\/978-1-4613-4217-5_58","DOI":"10.1007\/978-1-4613-4217-5_58"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bleskestad I, Bergrem H, Leivestad T, et al. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28(4):479-486. doi: https:\/\/doi.org\/10.1111\/ctr.12341","DOI":"10.1111\/ctr.12341"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Prakobsuk S, Sirilak S, Vipattawat K, et al. Hyperparathyroidism and increased fractional excretion of phosphate predict allograft loss in long-term kidney transplant recipients. Clin Exp Nephrol. 2016;21(5):926-931. doi: https:\/\/doi.org\/10.1007\/s10157-016-1370-9","DOI":"10.1007\/s10157-016-1370-9"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Nielsen HE, Christensen MS, Meisen F, T\u00f8rring S. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(3):e1. doi: https:\/\/doi.org\/10.1016\/j.kisu.2017.10.001","DOI":"10.1016\/j.kisu.2017.10.001"},{"key":"ref8","unstructured":"Nephro.ru [\u0418\u043d\u0442\u0435\u0440\u043d\u0435\u0442]. Professional association: Russian public association \u00abRussian dialysis society\u00bb. National clinical guidelines on CKD-MBD. 2015. (In Russ.). \u0414\u043e\u0441\u0442\u0443\u043f\u043d\u043e \u043f\u043e: http:\/\/www.nephro.ru\/content\/files\/recomendations\/ckdmbdNationalGuidelines.pdf. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 01.03.2023."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281-1287. doi: https:\/\/doi.org\/10.1093\/ndt\/gfh128","DOI":"10.1093\/ndt\/gfh128"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Nielsen HE, Christensen MS, Meisen F, T\u00f8rring S. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150. doi: https:\/\/doi.org\/10.1038\/kisup.2012.73","DOI":"10.1038\/kisup.2012.73"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 2006;93(3):491-507. doi: https:\/\/doi.org\/10.1093\/biomet\/93.3.491","DOI":"10.1093\/biomet\/93.3.491"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Setterberg L, Sandberg J, Elinder C-G, Nordenstrom J. Bone demineralization after renal transplantation: contribution of secondary hyperparathyroidism manifested by hypercalcaemia. Nephrol Dial Transplant. 1996;11(9):1825-1828. doi: https:\/\/doi.org\/10.1093\/oxfordjournals.ndt.a027676","DOI":"10.1093\/oxfordjournals.ndt.a027676"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Perrin P, Caillard S, Javier R, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653-2663. doi: https:\/\/doi.org\/10.1111\/ajt.12425","DOI":"10.1111\/ajt.12425"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol. 2013;33(2):191-203. doi: https:\/\/doi.org\/10.1016\/j.semnephrol.2012.12.019","DOI":"10.1016\/j.semnephrol.2012.12.019"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Bleskestad I, Bergrem H, Leivestad T, G\u00f8ransson L. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. Clin Transplant. 2011;25(5):E566-E570. doi: https:\/\/doi.org\/10.1111\/j.1399-0012.2011.01515.x","DOI":"10.1111\/j.1399-0012.2011.01515.x"},{"key":"ref16","unstructured":"Novokshon\u043ev KY, Karelina YV, Zemchenkov AY, et al. Chronic kidney disease mineral and bone disorder markers in screening study among dialysis patients in North-West federal region of Russia. Nefrologia. 2016;20(1):36-50. (In Russ.)."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Lehmann G, Ott U, Stein G, et al. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc. 2007;39(10):3153-3158. doi: https:\/\/doi.org\/10.1016\/j.transproceed.2007.10.001","DOI":"10.1016\/j.transproceed.2007.10.001"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"van Londen M, Aarts B, Deetman P, et al. Post-transplant hypophosphatemia and the risk of death-censored graft failure and mortality after kidney transplantation. Clin J Am Soc Nephrol. 2017;12(8):1301-1310. doi: https:\/\/doi.org\/10.2215\/cjn.10270916","DOI":"10.2215\/CJN.10270916"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Baia L, Heilberg I, Navis G, de Borst M. Phosphate and FGF-23 homeostasis after kidney transplantation. Nat Rev Nephrol. 2015;11(11):656-666. doi: https:\/\/doi.org\/10.1038\/nrneph.2015.153","DOI":"10.1038\/nrneph.2015.153"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Loffing J, L\u00f6tscher M, Kaissling B, et al. Renal Na\/H exchanger NHE-3 and Na-PO4 cotransporter NaPi-2 protein expression in glucocorticoid excess and deficient states. J Am Soc Nephrol. 1998;9(9):1560-1567. doi: https:\/\/doi.org\/10.1681\/ASN.V991560","DOI":"10.1681\/ASN.V991560"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Borowitz SM, Granrud GS. Glucocorticoids inhibit intestinal phosphate absorption in developing rabbits. J Nutr. 1992;122(6):1273-1279. doi: https:\/\/doi.org\/10.1093\/jn\/122.6.1273","DOI":"10.1093\/jn\/122.6.1273"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Haller M, Amatschek S, Wilflingseder J, et al. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. PLoS One. 2012;7(7):e39229. doi: https:\/\/doi.org\/10.1371\/journal.pone.0039229","DOI":"10.1371\/journal.pone.0039229"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Schwarz C, B\u00f6hmig G, Steininger R, et al. Impaired phosphate handling of renal allografts is aggravated under rapamycin\u2010based immunosuppression. Nephrol Dial Transplant. 2001;16(2):378-382. doi: https:\/\/doi.org\/10.1093\/ndt\/16.2.378","DOI":"10.1093\/ndt\/16.2.378"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kempe D, Dermaku-Sopjani M, Frohlich H, et al. Rapamycin-induced phosphaturia. Nephrol Dial Transplant. 2010;25(9):2938-2944. doi: https:\/\/doi.org\/10.1093\/ndt\/gfq172","DOI":"10.1093\/ndt\/gfq172"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98-107. doi: https:\/\/doi.org\/10.1016\/S1470-2045(14)71136-2","DOI":"10.1016\/S1470-2045(14)71136-2"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Bouquegneau A, Salam S, Delanaye P, et al. Bone disease after kidney transplantation. Clin J Am Soc Nephrol. 2016;11(7):1282-1296. doi: https:\/\/doi.org\/10.2215\/cjn.11371015","DOI":"10.2215\/CJN.11371015"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Kanaan N, Claes K, Devogelaer J, et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol. 2010;5(10):1887-1892. doi: https:\/\/doi.org\/10.2215\/cjn.00950110","DOI":"10.2215\/CJN.00950110"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Evenepoel P, Claes K, Meijers B, et al. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int. 2019;95(6):1461-1470. doi: https:\/\/doi.org\/10.1016\/j.kint.2018.12.024","DOI":"10.1016\/j.kint.2018.12.024"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Jeon H, Kim Y, Park S, et al. Association of serum phosphorus concentration with mortality and graft failure among kidney transplant recipients. Clin J Am Soc Nephrol. 2017;12(4):653-662. doi: https:\/\/doi.org\/10.2215\/cjn.07090716","DOI":"10.2215\/CJN.07090716"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Nakai K, Mitsuiki K, Kuroki Y, et al. Relative hypophosphatemia early after transplantation is a predictor of good kidney graft function. Clin Exp Nephrol. 2019;23(9):1161-1168. doi: https:\/\/doi.org\/10.1007\/s10157-019-01756-z","DOI":"10.1007\/s10157-019-01756-z"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Connolly G, Cunningham R, McNamee P, et al. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation. 2009;87(7):1040-1044. doi: https:\/\/doi.org\/10.1097\/tp.0b013e31819cd122","DOI":"10.1097\/TP.0b013e31819cd122"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Merhi B, Shireman T, Carpenter M, et al. Serum phosphorus and risk of cardiovascular disease, all-cause mortality, or graft failure in kidney transplant recipients: an ancillary study of the FAVORIT trial cohort. Am J Kidney Dis. 2017;70(3):377-385. doi: https:\/\/doi.org\/10.1053\/j.ajkd.2017.04.014","DOI":"10.1053\/j.ajkd.2017.04.014"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Pieper A, Buhle F, Bauer S, et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant. 2004;19(10):2630-2633. doi: https:\/\/doi.org\/10.1093\/ndt\/gfh446","DOI":"10.1093\/ndt\/gfh446"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Alagoz S, Trabulus S. Long-term evaluation of mineral metabolism after kidney transplantation. Transplant Proc. 2019;51(7):2330-2333. doi: https:\/\/doi.org\/10.1016\/j.transproceed.2019.01.181","DOI":"10.1016\/j.transproceed.2019.01.181"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Delos Santos R, Rossi A, Coyne D, Maw T. Management of post-transplant hyperparathyroidism and bone disease. Drugs. 2019;79(5):501-513. doi: https:\/\/doi.org\/10.1007\/s40265-019-01074-4","DOI":"10.1007\/s40265-019-01074-4"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Keyzer C, Riphagen I, Joosten M, et al. Associations of 25(OH) and 1,25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients. J Clin Endocrinol Metab. 2015;100(1):81-89. doi: https:\/\/doi.org\/10.1210\/jc.2014-3012","DOI":"10.1210\/jc.2014-3012"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Messa P, Regalia A, Alfieri C. Nutritional vitamin D in renal transplant patients: speculations and reality. Nutrients. 2017;9(6):550. doi: https:\/\/doi.org\/10.3390\/nu9060550","DOI":"10.3390\/nu9060550"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Cianciolo G, Galassi A, Capelli I, et al. Vitamin D in kidney transplant recipients: mechanisms and therapy. Am J Nephrol. 2016;43(6):397-407. doi: https:\/\/doi.org\/10.1159\/000446863","DOI":"10.1159\/000446863"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13167\/10439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:48:12Z","timestamp":1684172892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5,12]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13167","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}